Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18149004 | 0.90 | ROCK2 (0.47) | ROCK2KDM4EALDH1A1TP53RECQL | |
| SCHEMBL909584 | 0.81 | ALDH1A1 (0.45) | ROCK2KDM4EALDH1A1 | |
| SCHEMBL909156 | 0.81 | DDB1 (0.44) | KDM4EALDH1A1HSP90AA1HSP90AB1 | |
| SCHEMBL908402 | 0.81 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL909037 | 0.80 | HTR2A (0.40) | ALDH1A1DPP4 | |
| SCHEMBL909120 | 0.79 | IDO1 (0.46) | KDM4EALDH1A1TP53HTR1A | |
| SCHEMBL187797 | 0.78 | RBP4 (0.47) | TP53 | |
| SCHEMBL12462449 | 0.78 | RBP4 (0.47) | TP53 | |
| SCHEMBL908449 | 0.77 | CHRM2 (0.47) | TP53CHRNA7 | |
| SCHEMBL909447 | 0.76 | ALDH1A1 (0.38) | ROCK2ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9453000-B2 | Polycyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-8946266-B2 | Substituted triazole and imidazole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2454239-B1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICALS INC (US) | 2014-08-13 | — | — | EP | disclosed |
| EP-2181992-B1 | POLYCYCLIC COMPOUND | EISAI R&D MAN CO LTD (JP) | 2013-05-01 | — | — | EP | disclosed |
| EP-2559693-A1 | Polycyclic compound | Eisai R&D Management Co., Ltd. (JP) | 2013-02-20 | — | — | EP | disclosed |
| US-20120135981-A1 | NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-05-31 | — | — | US | disclosed |
| EP-2454239-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | Janssen Pharmaceuticals Inc. (US) | 2012-05-23 | — | — | EP | disclosed |
| US-7935815-B2 | Imidazoyl pyridine compounds and salts thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20110065696-A1 | IMIDAZOYL PYRIDINE COMPOUNDS AND SALTS THEREOF | KIMURA TEIJI | 2011-03-17 | — | — | US | disclosed |
| WO-2011006903-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110009619-A1 | POLYCYCLIC COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2181992-A1 | POLYCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009619-A1 | POLYCYCLIC COMPOUND | APP, BACE1, PSEN1 | ROCK2 1349/4885KDM4E 4536/4885ALDH1A1 1741/4885 |
| US-20120135981-A1 | NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, APH1A | ROCK2 3010/4885KDM4E 2831/4885ALDH1A1 1231/4885 |
| US-20110065696-A1 | IMIDAZOYL PYRIDINE COMPOUNDS AND SALTS THEREOF | APP, PSEN1, BACE1 | ROCK2 1549/4885KDM4E 3909/4885ALDH1A1 943/4885 |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | APP, BACE1, PSEN1 | ROCK2 850/4885KDM4E 4155/4885ALDH1A1 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.